These costs were partially offset by $14 of net reversals, primarily resulting from changes in estimated reserves from prior period initiatives.
SOs granted during the three months ended June 30, 2018 were 1,317.
As a result of this change, $9 and $20 of revenue was recorded, for the three and six months ended June 30, 2018, respectively, as Sales, which would have been previously recorded as Services revenue in prior periods.
In addition, the Equity in net income (loss) of Fuji Xerox for the three and six months ended June 30, 2018 includes after-tax restructuring and other charges of $4 and $83, respectively.
For the three and six months ended June 30, 2018, the incremental direct costs of obtaining a contract of $23 and $40, respectively, were deferred and the related amortization was $24 and $48, respectively.
Shares granted during the three months ended June 30, 2018 were 333.
We reported $56 and $110 of collections on beneficial interests as operating cash inflows on the Statement of Cash Flows for the three and six months ended June 30, 2017, respectively.
Accordingly, in 2018 these revenues are now reported as part of Sales.Operating cash flow from continuing operations attributable to Xerox for the six months ended June 30, 2018 was $451 million, as compared to $413 million for the prior year period.
Second quarter 2018 pre-tax income margin of 5.3% decreased 2.2-percentage points as compared to second quarter 2017.
The decrease in Net income from continuing operations attributable to Xerox for the three and six months ended June 30, 2018 as compared to the prior year periods was primarily due to Transaction and related costs, net and lower revenues.
•$1,018 million decrease from net debt activity.
•$76 million increase due to no acquisitions in 2018.
•$17 million increase from inventory due to timing of the product launch in prior year.
Non-financing interest expense for the three months ended June 30, 2018 was $27 million and increased $3 million as compared to the second quarter of 2017.101.CAL XBRL Taxonomy Extension Calculation Linkbase.
10.1 Director Appointment, Nomination and Settlement Agreement, dated as of May 13, 2018, by and among Registrant, Darwin Deason, the persons and entities listed on Schedule A thereto, William Curt Hunter, Jeffrey Jacobson, Robert J. Keegan, Charles Prince, Ann N. Reese, Stephen H. Rusckowski, Sara Martinez Tucker, Gregory Q.Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
See SEC File Number 001-04471.